MedTrace Logo

Liposomal Bupivacaine in Total Knee Arthroplasty

NCT02426164 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2016-03-22

No results posted yet for this study

Summary

Liposomal bupivacaine is a novel local anesthetic designed for prolonged pain relief. Despite its long-acting analgesic potential, liposomal bupivacaine is significantly more expensive than other local anesthetic alternatives. The primary aim of this investigation is to examine whether or not liposomal bupivacaine provides superior pain relief or clinically significant opioid-sparing effects versus a control to justify its cost.

Conditions

Interventions

DRUG

Liposomal bupivacaine

Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline

DRUG

bupivacaine HCl, morphine, epinephrine, methylprednisolone

Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone

Sponsors & Collaborators

  • Creighton University Medical Center

    collaborator OTHER

  • CHI Health Mercy Hospital

    collaborator OTHER

  • Miller Orthopedic Specialists

    lead OTHER

Principal Investigators

  • Clifford K Boese, MD · Miller Orthopedic Specialists

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02426164 on ClinicalTrials.gov